BME:ALMPharmaceuticals
Almirall (BME:ALM) Expands AI Dermatology Pipeline, Is The Valuation Gap Justified?
Almirall (BME:ALM) has drawn fresh investor attention after announcing a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology to co develop small molecule treatments for medical dermatology using CrystalO’s AI driven ion channel discovery platform.
See our latest analysis for Almirall.
The CrystalO agreement arrives at a time when Almirall’s share price has softened, with the stock down 4.39% over the past month and 18.91% year to date. The 3 year total...